报价延迟最少15分钟:2026/03/30 19:49 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.8317 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.68/-0.62
|
|
企业价值
62.42M
|
| 资产负债 |
|
每股账面净值
0.66
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
29.33K
|
|
每股收益
0.00
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings. |
